Compare MASS & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MASS | RPID |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.4M | 204.3M |
| IPO Year | 2020 | 2021 |
| Metric | MASS | RPID |
|---|---|---|
| Price | $6.03 | $3.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $8.00 |
| AVG Volume (30 Days) | ★ 248.0K | 128.7K |
| Earning Date | 06-01-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.47 | 11.48 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $56,197,000.00 | $28,051,000.00 |
| Revenue This Year | $18.58 | $19.91 |
| Revenue Next Year | $15.12 | $21.68 |
| P/E Ratio | $14.56 | ★ N/A |
| Revenue Growth | N/A | ★ 24.57 |
| 52 Week Low | $3.55 | $1.86 |
| 52 Week High | $9.34 | $4.94 |
| Indicator | MASS | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 39.48 |
| Support Level | $5.26 | $3.03 |
| Resistance Level | $6.06 | $3.76 |
| Average True Range (ATR) | 0.49 | 0.29 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 5.03 | 16.15 |
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.